# OnCo record aosaikang-pharmaceutical (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/aosaikang-pharmaceutical/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "aosaikang-pharmaceutical" ;
  schema:name "Aosaikang Pharmaceutical"@en ;
  schema:alternateName "Jiangsu Aosaikang Pharmaceutical"@en, "ASK Pharm"@en, "奥赛康药业"@en ;
  schema:description "Aosaikang Pharmaceutical is a China-based pharmaceutical company that leads 3 cancer trials in OnCo, testing the anti-CLDN18.2 antibody ASKB589 and the MET inhibitor ASKC202 in non-small-cell lung cancer and advanced solid tumours."@en ;
  schema:url <https://onco.cc/companies/aosaikang-pharmaceutical/>, <https://www.ask-pharm.com/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://www.ask-pharm.com/>, <https://clinicaltrials.gov/search?lead=Jiangsu%20Aosaikang%20Pharmaceutical%20Co.%2C%20Ltd.> ;
  onco:tag "ctgov-sponsor" ;
  schema:addressCountry "CN" ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:drugs <https://onco.cc/drugs/limertinib/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/pemetrexed/> ;
  onco:trials <https://onco.cc/trials/nct04632108/>, <https://onco.cc/trials/nct04143607/>, <https://onco.cc/trials/nct07109531/> .